Burchert, A
Saussele, S
Eigendorff, E
Müller, M C
Sohlbach, K
Inselmann, S
Schütz, C
Metzelder, S K
Ziermann, J
Kostrewa, P
Hoffmann, J
Hehlmann, R
Neubauer, A
Hochhaus, A
Article History
Received: 15 December 2014
Revised: 14 January 2015
Accepted: 20 January 2015
First Online: 25 February 2015
Competing interests
: Andreas Burchert: advisory Board Pfizer; Honoraria Bristol Meyers Squibb (BMS), Susanne Saussele: honoraria and Travel support BMS, Novartis, Ekkehard Eigendorff: honoraria and travel support Novartis, BMS, Ariad, Martin C. Müller: research support, honoraria and advisory role: Novartis, BMS, Ariad, Rüdiger Hehlmann: research support Novartis and BMS, Andreas Hochhaus: research support, honoraria and advisory role: Novartis, BMS, Ariad, Pfizer. The remaining authors declare no conflict of interest.